Nifurtimox
Treatment for Chagas Disease
Typical Dosage: 8-10 mg/kg/day for adults, 10-20 mg/kg/day for children, divided into 3 doses
Effectiveness
70%
Safety Score
30%
Clinical Trials
12
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
8-10 mg/kg/day for adults, 10-20 mg/kg/day for children, divided into 3 doses
Time to Effect
Weeks to months for parasiticidal effect, years for clinical benefit
Treatment Duration
60-90 days
Evidence Quality
HIGHNumber Needed to Harm (NNH)
4(Treat 4 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,500
Monitoring:$2,750
Side Effect Mgmt:$1,000
Total Annual:$5,250
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,681/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$9,545
Cost per Remission
$15,000
Comparison vs Benznidazole
Cost Difference
+$500/year
More expensive
QALY Difference
-0.05 QALYs
Worse outcomes
Dominance
No dominance
Nifurtimox Outcomes
for Chagas Disease
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+55%
Remission Rate
+35%
Common Side Effects
Gastrointestinal disturbances (anorexia, nausea, vomiting, abdominal pain)
+65%
Neurological symptoms (dizziness, insomnia, headache)
+40%
Peripheral neuropathy
+15%
Skin reactions
+15%
Weight loss
+15%
Sources:
Active Clinical Trials
1 active trial recruiting for Nifurtimox in Chagas Disease
An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
NCT05477953NOT YET RECRUITING
50 participants
OBSERVATIONAL
Multiple Locations, United States +9 more
Started: Jun 30, 2026
Completed Clinical Trials
9 completed trials for Nifurtimox in Chagas Disease
New Therapies and Biomarkers for Chagas Infection
NCT03981523COMPLETEDPHASE2
450 participants
INTERVENTIONAL
Cochabamba, Bolivia +2 more
Started: Dec 18, 2019
Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients
NCT02606864COMPLETEDPHASE1
36 participants
INTERVENTIONAL
Buenos Aires, Argentina
Started: Dec 1, 2015
Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina
NCT03784391COMPLETED
3K participants
OBSERVATIONAL
Multiple Locations, Argentina
Started: Dec 14, 2018
Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg
NCT03350295COMPLETEDPHASE1
48 participants
INTERVENTIONAL
Buenos Aires, Argentina
Started: Jun 14, 2018
Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study
NCT03334838COMPLETEDPHASE1
36 participants
INTERVENTIONAL
Buenos Aires, Argentina
Started: Jun 10, 2019
A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
NCT02625974COMPLETEDPHASE3
330 participants
INTERVENTIONAL
La Plata, Argentina +24 more
Started: Jan 27, 2016
Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients
NCT01927224COMPLETEDPHASE1
37 participants
INTERVENTIONAL
Buenos Aires, Argentina
Started: Nov 1, 2013
Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease
NCT01744405COMPLETED
12 participants
OBSERVATIONAL
Buenos Aires, Argentina
Started: Dec 1, 2012
Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation
NCT03708133COMPLETEDPHASE1
24 participants
INTERVENTIONAL
Buenos Aires, Argentina
Started: Dec 5, 2018